Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, CVS Health Corporation (CVS) has a Wall Street consensus price target of $94.92, based on estimates from 41 covering analysts. With the stock currently trading at $79.90, this represents a potential upside of +18.8%. The company has a market capitalization of $101.55B.
Analyst price targets range from a low of $90.00 to a high of $103.00, representing a 14% spread in expectations. The median target of $93.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 34 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CVS trades at a trailing P/E of 57.5x and forward P/E of 11.1x. Analysts expect EPS to grow +417.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $293.83, with bear and bull scenarios of $162.36 and $636.79 respectively. Model confidence stands at 68/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CVS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonCVS Health Corporation (CVS) has a consensus 12-month price target of $94.92, implying 18.8% upside from $79.9. The 41 analysts covering CVS see moderate appreciation potential.
CVS has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 34 Buy/Strong Buy ratings. The consensus 12-month price target of $94.92 implies 18.8% upside from current levels.
With a forward P/E of 11.1497x, CVS trades at a relatively low valuation. The consensus target of $94.92 implies 18.8% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $103 for CVS, while the most conservative target is $90. The consensus of $94.92 represents the median expectation. Our quantitative valuation model projects a bull case target of $637 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CVS is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 2 have Strong Buy ratings, 32 have Buy ratings, 7 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CVS stock forecast based on 41 Wall Street analysts shows a consensus price target of $94.92, with estimates ranging from $90 (bear case) to $103 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $294, with bear/bull scenarios of $162/$637.
Our quantitative valuation model calculates CVS's fair value at $294 (base case), with a bear case of $162 and bull case of $637. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 68/100.
CVS trades at a forward P/E ratio of 11.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 57.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on CVS, with a "Buy" consensus rating and $94.92 price target (18.8% upside). 34 of 41 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CVS analyst price targets range from $90 to $103, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $94.92 consensus represents the middle ground. Our model's $162-$637 range provides an independent fundamental perspective.